Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Unknown 3Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 37Neoplasms 3Neoplasm Metastasis 3Breast Diseases 3Neoplasms by Site 2Triple Negative Breast Neoplasms 1Skin Diseases 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Breast Neoplasms, Male 1Breast Neoplasm Female 1Breast Cancer Female 1Advanced Breast Carcinoma 1

Interventions

palbociclib 3Anastrozole 3pertuzumab 2Trastuzumab 2Gonadotropin-Releasing Hormone 2AZD9833 2trastuzumab deruxtecan 1taxane 1ribociclib 1abemaciclib 1Letrozole 1Genotype 1Fulvestrant 1Denosumab 1Body Height 1Blood Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Breast Diseases × Anastrozole × Clear all
NCT04964934 2026-04-21

SERENA-6

AstraZeneca

Phase 3 Active not recruiting
315 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT04711252 2025-10-14

SERENA-4

AstraZeneca

Phase 3 Active not recruiting
1,370 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
44 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡